COMMUNIQUÉS West-GlobeNewswire
-
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
23/03/2026 -
SafeSpace Global Secures Shareholder Approval to Increase Authorized Shares of Common Stock
23/03/2026 -
Vantive Accelerates U.S. Home Therapy Transformation With New Digital and Patient Support Innovations
23/03/2026 -
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
23/03/2026 -
Cortexa Advances Commercialisation of MDMA Supply in Australia
23/03/2026 -
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
23/03/2026 -
AdipoPharma Enters Clinic with First-in-Class Therapy Targeting Type 2 diabetes with the potential to maintain muscle mass
23/03/2026 -
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
23/03/2026 -
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
23/03/2026 -
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
23/03/2026 -
Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
23/03/2026 -
Checkerspot Announces Breakthrough, using Microalgae to Produce Palmitoleic Acid Oil at Scale, Opening a New Pathway to Omega-7s
23/03/2026 -
Standard Dental Labs Inc. Engages Strategic Advisor to Support Lab Acquisition Strategy
23/03/2026 -
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
23/03/2026 -
NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update
23/03/2026 -
Trading by management and close relations of management
23/03/2026 -
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
23/03/2026 -
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
23/03/2026 -
Trading in GN Store Nord shares by board members, executives and associated persons
23/03/2026
Pages